NEUROBO PHARMACEUTICALS, INC. Financials NeuroBo Pharmaceuticals, Inc.
Equities
NRBO
US64132R4048
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.03 USD | +1.77% |
|
+6.05% | +9.02% |
| 09/05 | NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 08/05 | Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 136.8 | 86.24 | 32.44 | 13.61 | 17.93 | 19.43 | - | - |
| Enterprise Value (EV) 1 | 136.8 | 86.24 | 32.44 | 13.61 | 17.93 | 19.43 | 19.43 | 19.43 |
| P/E ratio | -2.14 x | -2.87 x | -1.85 x | -0.13 x | -1.5 x | -0.97 x | -1.29 x | -1.71 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | -1.16 x | - | -0.81 x | -0.87 x | -0.93 x |
| FCF Yield | - | - | - | -86% | - | -124% | -116% | -108% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 65.1 | 68.4 | 111 | 2,372 | 4,852 | 4,906 | - | - |
| Reference price 2 | 2,100 | 1,260 | 292.8 | 5.740 | 3.697 | 4.030 | 4.030 | 4.030 |
| Announcement Date | 30/03/20 | 15/04/21 | 31/03/22 | 30/03/23 | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.18 | -29.72 | - | -19.63 | -15.89 | -25.48 | -29.47 | -33.8 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -21.31 | -29.68 | - | -13.97 | -12.47 | -25.3 | -29.31 | -33.62 |
| Net income 1 | -21.31 | -29.68 | -15.28 | -13.97 | -12.47 | -25.3 | -29.31 | -33.62 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -979.2 | -439.2 | -158.4 | -43.44 | -2.460 | -4.157 | -3.133 | -2.360 |
| Free Cash Flow 1 | - | - | - | -11.71 | - | -24 | -22.44 | -20.99 |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 30/03/20 | 15/04/21 | 31/03/22 | 30/03/23 | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -10.43 | -2.52 | -3.806 | -3.893 | -5.667 | -6.881 | -6.037 | -6.635 | -7.195 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -4.676 | -2.604 | -0.734 | -3.818 | -5.314 | -6.714 | -6.01 | -6.57 | -7.144 |
| Net income 1 | -3.113 | -4.676 | -2.604 | -0.734 | -3.818 | -5.314 | -6.714 | -6.01 | -6.57 | -7.144 |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -28.00 | - | -0.4800 | -0.1600 | -0.7200 | -2.280 | -1.320 | -0.9033 | -0.8800 | -0.9167 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 14/11/22 | 30/03/23 | 12/05/23 | 09/08/23 | 13/11/23 | 28/03/24 | 09/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -11.7 | - | -24 | -22.4 | -21 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 30/03/20 | 15/04/21 | 31/03/22 | 30/03/23 | 28/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.03
USD
Average target price
36.5
USD
Spread / Average Target
+805.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.02% | 19.43M | |
| +5.66% | 109B | |
| +11.23% | 105B | |
| -0.38% | 22.25B | |
| -12.15% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -10.09% | 16.85B | |
| +3.33% | 13.76B | |
| +36.58% | 12.46B |
- Stock Market
- Equities
- NRBO Stock
- Financials NeuroBo Pharmaceuticals, Inc.